Journal of the American Academy of Dermatology
Volume 83, Issue 6, Supplement, December 2020, Page AB145
15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
References (0)
Cited by (0)
Commercial disclosure: This study was sponsored by Janssen Research & Development.
Copyright © 2020 Published by Mosby, Inc.